Efficacy of xanomeline+trospium (Cobenfy™) and comparison with second-generation antipsychotics

In September 2024, the United States Food and Drug Administration (FDA) approved the combination of two drugs—xanomeline and trospium—in the same capsule (under the brand name Cobenfy™) for the treatment of schizophrenia in adults. The combination was previously known as KarXT. This combination medication is receiving a lot of attention because, unlike all previous medications for the treatment…